Scarica l'app Stockscreener
1.08
8.47%
-0.10
Dopo l'orario di chiusura:
1.06
-0.02
-1.85%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.18
Aprire:
$1.17
Volume 24 ore:
2.40M
Relative Volume:
2.41
Capitalizzazione di mercato:
$139.51M
Reddito:
-
Utile/perdita netta:
$-26.91M
Rapporto P/E:
-4.9091
EPS:
-0.22
Flusso di cassa netto:
$-19.57M
1 W Prestazione:
+6.93%
1M Prestazione:
+35.27%
6M Prestazione:
+83.14%
1 anno Prestazione:
-22.30%
Intervallo 1D:
$1.05
$1.20
Intervallo di 1 settimana:
$0.9702
$1.29
Portata 52W:
$0.5526
$1.66
Atossa Therapeutics Inc Stock (ATOS) Company Profile
Nome
Atossa Therapeutics Inc
Settore
Industria
Telefono
206.588.0256
Indirizzo
10202 5TH AVENUE NE, SEATTLE, WA
Confronta ATOS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ATOS
Atossa Therapeutics Inc
|
1.08 | 152.42M | 0 | -26.91M | -19.57M | -0.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2018-01-26 | Iniziato | Maxim Group | Buy |
Atossa Therapeutics Inc Borsa (ATOS) Ultime notizie
Regression analysis insights on Atossa Therapeutics Inc. performancePortfolio Gains Summary & High Accuracy Trade Signal Alerts - newser.com
What MACD and RSI say about Atossa Therapeutics Inc.July 2025 Institutional & High Conviction Buy Zone Picks - newser.com
Can Atossa Therapeutics Inc. (YAG2) stock stage a strong rebound this quarterWeekly Investment Recap & Weekly Watchlist of Top Performers - newser.com
Can a trend reversal in Atossa Therapeutics Inc. lead to recoveryEarnings Growth Report & Stepwise Swing Trade Plans - newser.com
Atossa Therapeutics and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Pueblo Chieftain
Is Atossa Therapeutics Inc. stock ready for a breakoutJuly 2025 Sector Moves & Breakout Confirmation Alerts - newser.com
How to forecast Atossa Therapeutics Inc. trends using time seriesGap Down & Weekly Market Pulse Updates - newser.com
Is Atossa Therapeutics Inc. stock entering bullish territoryMarket Growth Report & Fast Moving Stock Trade Plans - newser.com
Comparing Atossa Therapeutics Inc. in custom built stock radars2025 Earnings Surprises & Stepwise Entry and Exit Trade Signals - newser.com
Published on: 2025-10-10 02:05:17 - newser.com
Weiss Ratings Reiterates "Sell (D-)" Rating for Atossa Genetics (NASDAQ:ATOS) - MarketBeat
Can Atossa Therapeutics Inc. (YAG2) stock deliver double digit returnsOptions Play & Weekly Breakout Watchlists - newser.com
Signal strength of Atossa Therapeutics Inc. stock in tech scannersTrade Entry Report & Weekly Momentum Picks - newser.com
Can Atossa Therapeutics Inc. (YAG2) stock reach $200 price targetQuarterly Trade Report & Low Volatility Stock Recommendations - newser.com
Atossa Therapeutics (ATOS) Announces Upcoming Virtual Meeting - GuruFocus
Atossa streamlines breast cancer trial to focus on 2026 NDA plans - Investing.com
Atossa Therapeutics streamlines Evangeline breast cancer clinical trial to prioritize for 2026 NDA-enabling activities - MarketScreener
40–65-Patient EVANGELINE Redesign: Atossa Prioritizes 2026 NDA‑Enabling Activities, Reduces Study Costs - Stock Titan
Atossa Therapeutics Inc. stock retracement – recovery analysisEarnings Growth Report & Free Fast Gain Swing Trade Alerts - newser.com
Can Atossa Therapeutics Inc. stock hit analyst price targetsWeekly Risk Report & Consistent Income Trade Recommendations - newser.com
Atossa Therapeutics appoints Janet Rea as SVP of R&D By Investing.com - Investing.com Nigeria
Atossa Therapeutics appoints Janet Rea as SVP of R&D - Investing.com
What drives Atossa Therapeutics Inc YAG2 stock priceDouble Top/Bottom Patterns & Superior Trading Ideas - earlytimes.in
Atossa Therapeutics Names Janet R. Rea, MSPH, as Senior Vice President, R&D to Accelerate (Z)-Endoxifen Toward Key Regulatory Milestones - StreetInsider
Veteran Drug Approval Expert Returns to Atossa Therapeutics to Advance Breakthrough Breast Cancer Treatment - Stock Titan
Goldman Sachs Group Inc. Lowers Holdings in Atossa Genetics Inc. $ATOS - Defense World
NioCorp and Atossa Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - The Daily Jeffersonian
What analysts say about Atossa Therapeutics Inc stockSector-Based Investing & Build Capital Safely - earlytimes.in
Atossa Therapeutics Inc Azioni (ATOS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Atossa Therapeutics Inc Azioni (ATOS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Remmel H. Lawrence | Director |
Mar 26 '25 |
Buy |
0.70 |
10,000 |
7,000 |
10,257 |
5.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):